Ophtec flag

Press release: OPHTEC's pre-loaded Capsular Tension Ring (CTR) “Ringject” CFDA approved and soon commercially available in China

22-02-2019

Groningen, The Netherlands (February 21, 2019)OPHTEC BV, a pioneer in intraocular lenses (IOLs), was granted CFDA approval for the pre-loaded capsular tension ring (CTR) “Ringject” in China.

CTRs were originally introduced to strengthen the zonule in eyes with zonular dehiscence (ZD) in cataract and lens surgery. They also prevent capsular phimosis in eyes at risk for postoperative capsular shrinkage. Tiago Guerreiro, Global Marketing Director at OPHTEC BV: “The main indication for the use of CTRs is still the management of ZD but we see surgeons using CTRs for other purposes too.”

CTRs are widely used in Europe in combination with premium IOLs to ensure lens stability and to avoid tilt and rotation. “We see a clear trend in the use of the pre-loaded Ringject with multifocal IOLs. It started a few years ago in Europe and other countries are following as surgeons see the advantages of (multifocal) IOL stabilization in the capsular bag.” Mr. Guerreiro continued. “We foresee a significant growth on the pre-loaded CTRs demand in China as the product offers easy handling. The CFDA approval of Ringject is another step forward on OPHTEC’s commitment to the Chinese ophthalmic community.”

Ringject is a pre-loaded, single use capsular tension ring designed to be self-loading for surgical convenience. The product is CE and FDA approved and is available for commercial use in Europe, South Korea and The United States. Ringject will soon be commercially available in China too.


About CTRs

OPHTEC Capsular Tension Rings are indicated for the stabilization of the capsular bag in the presence of weakened or compromised zonules. Some of the benefits may include circular expansion and stabilization of the capsular bag as well as safe IOL centration in eyes with zonular dehiscence. The CTRs helps preventing IOL decentration after capsular shrinking, offers stabilized conditions during phaco emulsification surgery, reduced risk of capsular fibrosis and may improve visual acuity when implanted along with premium IOL.


About cataract

Cataract is a clouding of the eye's natural lens, causing vision loss. Cataract can occur in either or both eyes. If left untreated, the clouding can eventually lead to legal blindness or even total blindness. Most cataracts are related to ageing, but cataracts can also be present at birth or develop later in life caused by physical injury or trauma.  The lens lies behind the iris and the pupil. In a normal eye, light passes through the transparent lens. The lens is made of mostly water and protein. As we age, some of the protein may clump together and start to cloud a small area of the lens. This is a cataract. Over time, the cataract may grow larger and cloud more of the lens, making it harder to see.


About OPHTEC BV

OPHTEC was founded in 1983 by ophthalmologist prof. Jan Worst (1925 - 2015) and his wife Mrs Anneke Worst-van Dam. His inventions such as the Artisan lens have changed ophthalmology forever and today it is the company’s vision to design, produce and market clinically innovative ophthalmic products for patients and doctors, with a focus on perfection.


For more information please contact Mr. Tiago Guerreiro, Global Marketing Director at OPHTEC BV (t.guerreiro@ophtec.com). 

Previous page
United States